KineMed, Inc. has renewed a non-exclusive research collaboration with Pfizer for the advancement of novel approaches to metabolic disease, in particular Type II Diabetes. KineMed will use its proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
“We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform,” said Dr. Scott Turner, executive vice president, R&D at KineMed. “We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”